Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Gross Profit (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Gross Profit for 3 consecutive years, with $101.8 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 21.56% to $101.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $394.9 million through Dec 2025, up 28.44% year-over-year, with the annual reading at $394.9 million for FY2025, 28.44% up from the prior year.
  • Gross Profit hit $101.8 million in Q4 2025 for Immunocore Holdings, down from $103.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $103.2 million in Q3 2025 to a low of $54.4 million in Q1 2023.
  • Historically, Gross Profit has averaged $79.2 million across 3 years, with a median of $76.7 million in 2024.
  • Biggest five-year swings in Gross Profit: increased 19.67% in 2024 and later soared 32.44% in 2025.
  • Year by year, Gross Profit stood at $70.0 million in 2023, then rose by 19.67% to $83.7 million in 2024, then increased by 21.56% to $101.8 million in 2025.
  • Business Quant data shows Gross Profit for IMCR at $101.8 million in Q4 2025, $103.2 million in Q3 2025, and $96.9 million in Q2 2025.